Clinical study to evaluate the efficacy of itriphal zamani in Migraine

A RANDOMIZED TWO ARM ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE EFFICACY OF UNANI FORMULATION ITRIFAL ZAMANI IN THE MANAGEMENT OF MIGRAINE SHAQEEQA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087477

Enrollment

Registered

2025-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: Itrifal zamani: 10 gms ,Bd after meals with two follow ups with interval of 15 days Control Intervention1: Tab flunarizine: 5mg,od after meals with 2 follow ups at interval of 15 days

Eligibility

Inclusion criteria

Inclusion criteria: Patient following ICHD criteria patient following midas scale upto grade 3

Exclusion criteria

Exclusion criteria: 1)pregnant & lactacting women 2)patient with other migraine variants like hemiplegia migraine,opthalnic migraine ,migarinus status. 3)head injury, pan sinusitis,brain tumors. 4)uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
To evaluate the clinical efficacy of itrifal zamani in cases of shaqeeqaTimepoint: once in 2-4 weeks	—

Secondary

Measure	Time frame
To provide adequate relief from symptomsTimepoint: once in 2 weeks	—

Countries

India

Contacts

Public ContactDr Syed Abdul Khadir Hussaini

Government Nizamia Tibbi College

drsakhussaini@gmail.com9704888561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026